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Abstract
The Ets1 proto-oncoprotein is a member of the Ets family of transcription factors that share a
unique DNA binding domain, the Ets domain. The DNA binding activity of Ets1 is controlled by
kinases and transcription factors. Some transcription factors, such as AML-1, regulate Ets1 by
targeting its autoinhibitory module. Others, such as Pax-5, alter Ets1 DNA binding properties. Ets1
harbors two phosphorylation sites, threonine-38 and an array of serines within the exon VII
domain. Phosphorylation of threonine-38 by ERK1/2 activates Ets1, whereas phosphorylation of
the exon VII domain by CaMKII or MLCK inhibits Ets1 DNA binding activity. Ets1 is expressed by
numerous cell types. In haemotopoietic cells, it contributes to the regulation of cellular
differentiation. In a variety of other cells, including endothelial cells, vascular smooth muscle cells
and epithelial cancer cells, Ets1 promotes invasive behavior. Regulation of MMP1, MMP3, MMP9 and
uPA as well as of VEGF and VEGF receptor gene expression has been ascribed to Ets1. In tumors,
Ets1 expression is indicative of poorer prognosis.
Introduction
Ets proteins comprise a family of transcription factors that
share a unique DNA binding domain, the Ets domain [1–
4]. The name "Ets" stems from a sequence that was
detected in an avian erythroblastosis virus, E26, where it
formed a transforming gene together with ∆gag and c-myb
[5,6]. The newly discovered sequence was called E26
transformation specific sequence or Ets. Later, a cellular
homologue to the viral ets (v-ets) gene, c-ets1, was found
suggesting that v-ets derived from c-ets1 [7,8].
Structure of c-Ets1
The c-Ets1 protein is closely related to c-Ets2. It is believed
that these two proteins derived from the same ancestor
gene by duplication [9,10]. The genomes of Drosophila
and sea urchin contain only one Ets1-related gene, D-ets2
(Pointed) and SU-ets2, respectively, whereas birds, reptiles,
amphibians and mammals harbor both the ets1 and ets2
genes [11,12]. In humans, the ets1  and  ets2  genes are
located on two distinct chromosomes, ets1 on chromo-
some #11, ets2 on chromosome #21 [7]. No ets1-related
gene has been found in the genome of the Caenorhabditis
elegans, although this nematode worm does express a vari-
ety of other Ets proteins [13].
In birds and reptiles, the c-ets1 locus contains two differ-
ent start sites leading to the expression of p68c-ets1 and
p54c-ets1. These two proteins differ in their N-terminal
sequence [14]. Exons α (I) and β (II) code for the N-termi-
nus of p68c-ets1, whereas exon I54 (A) encodes the N-termi-
nus of p54c-ets1 (Fig. 1). The exon β domain of p68c-ets1
shows a high degree of homology to the N-terminus of c-
Ets2 and was thus called the Ets1-beta/Ets2-conserved
sequence (BEC). In mammals, only exon I54 is present,
therefore, p68c-ets1 is not expressed.
The human TATA-less ets1 gene contains eight exons (A,
III-IX) [15]. Transcripts either harbor all exons or lack
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exon IV- or exon VII- or exon IV/VII-specific sequence
[16]. Only two proteins are generated from these RNAs,
p54c-ets1 (full length Ets1) and p42c-ets1 (∆VII-Ets1) (Fig.
1). The Ets1 protein sequence is highly conserved among
species. E.g., the DNA and protein sequence of chicken
Ets1 is 85% or 95%, respectively, identical to the corre-
sponding sequence of human Ets1 [17]. The Ets1 protein
can be divided into six domains, A-F (Fig. 1). The E-
domain is the DNA binding Ets-domain. The adjoining D-
(or exon VII-) domain and the F-domain are regulatory
domains that control the activity of the E-domain. The A-
und B- domains also function as regulatory units, whereas
the C-domain is the activation domain of p54c-ets1 and
p42c-ets1.
The Ets domain
Ets domain proteins belong to the superfamily of winged
helix-turn-helix (wHTH) DNA-binding proteins which
includes also hepatocyte nuclear factor HFN-3γ, heat
shock factor HSF and catabolite activator protein CAP
[18]. The Ets domain, composed of 85 amino acids, com-
prises three α-helices and four β-strands that are arranged
in the order H1-S1-S2-H2-H3-S3-S4 (Fig. 2). The Ets
domain specifically recognizes DNA sequences that con-
tain a GGAA/T core element [19]. In the Ets1 protein, the
Ets domain stretches from residue 331 to residue 415. As
revealed by NMR spectroscopy, the helix H3 of Ets1 inter-
acts with the GGAA motif in the major groove, whereas
the "wing", formed by the loop between strands 3 and 4
of the β-sheet, contacts the 5' minor groove [20]. Helices
1–3, the "turn" between helix H2 and helix H3 contribute
to the interaction of the Ets1 domain with the 3' minor
groove. Strikingly, the distantly related Ets factor PU.1
binds in a similar way to DNA [21] demonstrating that the
Ets domain/DNA interaction is highly preserved. How-
ever, Ets proteins differ significantly in their preference for
the sequence flanking the GGAA/T core motif. The con-
sensus sequence for Ets1 is PuCC/a-GGAA/T-GCPy as
determined by several rounds of selection and amplifica-
tion of Ets1-binding sites [19]. Yet, many natural Ets1-
responsive GGAA/T elements differ from this consensus
sequence [22]. It is possible that other transcription
The domains of the Ets1 protein Figure 1
The domains of the Ets1 protein. BEC = Ets1-beta/Ets2-conserved sequence, TAD = transactivation domain, NLS = 
nuclear localization sequence, HI-1/2 = inhibitory α-helices 1/2, H4 = α-helix 4, S = serines, T = threonine-38.
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factors may facilitate Ets1 binding to unfavorable DNA
sequences (see below).
Ets1 is predominantly found in the nucleus, though its
presence in the cytoplasm of quiescent endothelial cells as
well as of endometrial and ovarian cancer cells has also
been demonstrated [23–25]. Deletion of the C-terminal
part of the Ets domain excludes Ets1 from the nucleus [26]
showing that the nuclear localization sequence of Ets1
resides on its Ets domain (Fig. 1).
The Pointed domain and the Ras-responsive 
phosphorylation site
The Pointed (PNT) domain, named after the Ets1-related
protein Pointed-P2 in Drosophila, is shared by many Ets
proteins. The Ets1 PNT domain, located between amino
acid 54 and 135, consists of five α-helices. Though origi-
nally thought to adopt a helix-loop-helix (HLH) confor-
mation, NMR analysis revealed that the PNT domain
forms a globular structure that does not resemble any
other known protein- or DNA-binding interaction inter-
face [27]. The N-terminal sequence of Ets1 contains also a
Ras-responsive phosphorylation site at threonine-38
[28,29] (Fig. 1). Phosphorylation of this residue strongly
increases the transcriptional activity of Ets1.
The inhibitory module of Ets1 Figure 2
The inhibitory module of Ets1. Details are described in the text. For simplicity, only the major contact of the H3-helix with 
DNA is shown. ID = inhibitory domain, H = α-helix, S = β-sheet, HI= inhibitory α-helix, I-1 = HI-1 after having unfolded to a 
random coil, AML1 = acute-myeloid-leukemia-1
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Table 1: Ets1 interacting proteins
Proteins that cooperate with Ets1
protein responsive gene(s) comments reference
AML-1 TCRα, TCRβ, osteopontin, GM-CSF mutual blockage of the negative regulatory domains 
induces cooperative binding of Ets1 and AML-1
[47–52]
ATF-2 TCRα binds stronger to Ets1 when it lacks dimerization domain [48]
AP-1 (c-Jun/c-Fos) GM-CSF, TIMP-1, polyoma enhancer, MMP-1 [53–57]
CBP/p300 MMP-3 [42,58]
ERK1/2 uPA, MMP-3, prolactin phosphorylates threonine-38 [28,29,59,60]
Ets1 MMP-3 requires presence of a palindromic sequence [61]
Estrogen receptor artificial promoter Ets1 cooperates with unliganded receptor [62]
GATA3 human interleukin-5 requires presence of PMA and ionomycin [63]
HIF-2α VEGFR-2 (Flk-1) [64]
HTLV-I Tax PTHrP (P3 promoter), interleukin-5 Tax forms ternary complex with Ets1 and Sp1, enhances 
GATA3/Ets1 cooperation
[63,65]
LEF-1 TCRα LEF-1 induces DNA-bending that facilitates Ets1/ATF2 
interaction
[48]
c-Myb α4 integrin, mim-1, lck type I Ets1/c-Myb synergism blocks repression by ZEB [66–68]
NFAT HIV-LTR [69]
NF-κB GM-CSF, HIV-LTR [56,69]
Pax5 mb-1 allows Ets1 to bind to unfavorable GGAG, changes 
contacts of Y395 (H3-helix) with DNA
[70–72]
Pit-1/GHF-1 prolactin [73]
PKCα PTHrP (P3 promoter) constitutively active form increases Ets1 activity and 
induces phosphorylation of exon VII domain
[74]
mutant p53 MDR1 wildtype p53 does not bind to and synergize with Ets1 [75]
wildtype p53 mdm2, bax requires presence of CBP, and UV-radiation, Ets1 
necessary for p53-dependent apoptosis in ES cells
[76]
Ras uPA, MMP-3, prolactin induces ERK1/2-dependent phosphorylation of 
threonine-38
[28,29]
Smad3/4 PTHrP (P3 promoter) requires presence of TGFβ [77]
SPBP synthetic promoter SPBP = stromelysin-1 PDGF responsive element binding 
protein
[78]
Sp1 PTHrP, MRG1, HTLV-I LTR, integrin αIIb, P4 
promoter of MVMp, FasL
Ets1/Sp1 bind cooperatively to DNA [79–83]
Sp100 MMP3, synthetic promoters does not activate ∆VII-Ets1 [45]
Stat5 GAS/Ets elements [84]
TFE3 immunoglobulin µ heavy-chain gene basic helix-loop-helix domain of TFE3 sufficient for Ets1 
binding, several Ets1 domains involved in binding
[46]
huUBC9 synthetic promoter [85]
USF-1 HIV-LTR [86]
Vitamin D receptor 
(VDR)
artificial promoter Ets1 induces conformational change of VDR, in the 
presence of Ets1 activation by VDR does not require 
AF2-domain
[62]
Proteins that repress Ets1 activity
protein responsive gene comments reference
CaMKII GM-CSF blocks AML-1/Ets1 cooperative effect by phosphorylating 
exon VII domain
[47]
Daxx/EAPI (Ets1-
associated protein)
MMP1 and BCL2 a nuclear protein that cooperates with Ets1 to repress 
transcription
[87]
EAPII (Ets1-associated 
protein)
MMP1 a nuclear protein that attenuates Ets1/AP1 cooperative 
effect, inhibits migration of epithelial cells
[55]
MafB (AP-1 likeprotein) transferrin receptor, porphobilinogen 
deaminase
suppresses Ets1-dependent activation of erythoid-specific 
genes
[88]
ZEB α4 integrin repression of Ets1 by ZEB is blocked when Ets1 
synergizes with c-Myb
[67]Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/29
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The exon VII domain, the autoinhibitory module and 
calcium-dependent phosphorylation
The D- or exon VII domain resides in the Ets1 protein
between amino acids 243 and 331 (Fig. 1). It comprises
two regulatory units. The C-terminal unit is part of an
autoinhibitory module [30], the N-terminal sequence
contains a calcium-responsive phosphorylation site [31].
The two units are functionally connected as phosphoryla-
tion within the N-terminal sequence increases the inhibi-
tory effect of the C-terminal unit [32]. An inhibitory
sequence within the exon VII domain was first proposed
when studies showed that deletion of the exon VII
domain results in an enhanced DNA binding activity [33].
Since a similar increase in DNA binding was also observed
when the C-terminus (F-domain) was deleted or mutated
[34–36] an interplay between the exon VII domain and
the C-terminus of the Ets1 protein was suggested. Later, it
became clear that the exon VII-specific sequences between
301 and 331 and the C-terminal sequence between 415
and 440 form a metastable autoinhibitory module [30].
The key structural unit was found to be formed by three
inhibitory helices (HI-1 and HI-2 within exon VII domain
and H4 at the C-terminus). These helices cooperatively
block Ets DNA binding activity by interacting with the H1-
helix of the Ets domain and, thereby, freeze the Ets
domain in a closed confirmation [37,38]. The blockage is
transient and can be relieved when the HI-1 helix sponta-
neously unfolds to form a random coil (Fig. 2). This struc-
tural switch allows other proteins, such as the
transcription factor AML-1 (acute myeloid leukemia-1), to
modulate Ets1 DNA binding activity [37].
Calcium-dependent phosphorylation of the exon VII
domain also interferes with the activity of the Ets1 autoin-
hibitory module and decreases the stability of the Ets1
protein in T-lymphocytes [39]. It involves phosphoryla-
tion of a cluster of serines, including Ser251, Ser257, Ser282
and Ser285, within the N-terminal part of exon VII [31]
(Fig. 1). It results in stabilization of the inhibitory struc-
ture and in a strongly reduced DNA binding activity [32].
The natural splicing variant ∆VII-Ets1 lacks an essential
part of the autoinhibitory module and the calcium-sensi-
tive serines. This confers the ability to ∆VII-Ets1 to form
stable complexes with DNA [40] and renders this protein
resistant to the negative action of calcium. The viral v-Ets1
protein contains a modified C-terminus which inactivates
the autoinhibitory module as well and allows v-Ets1 to
bind stably to DNA [36].
The activation domains
The activation domain or C-domain is located between
amino acids 130–242 and contains a high content of
acidic residues. It is essential for p54c-ets1 and p42c-ets1 to
activate transcription [41]. Chicken p68c-ets1 harbors a sec-
ond N-terminal transcriptional domain, BEC (as men-
tioned above), that it shares with Ets2 [10]. The C-domain
is also necessary for the interaction of Ets1 with the CREB
binding factor (CBP)/p300 [42]. CBP and p300 have dual
functions as histone acetyl transferases and co-activators
that facilitate cooperativity between transcription factors
[43,44].
Interaction with other proteins
Ets1 functionally and physically interacts with a variety of
transcription factors and other proteins (Table 1). Most
proteins that directly contact Ets1 bind to the Ets domain
(Fig. 3). Others associate with the exon VII domain, the N-
terminal part of Ets1 or the activation domain. Some pro-
teins, such as Sp100 or TFE3, interact with several
domains of the Ets1 protein [45,46].
Transcription factors
A number of transcription factors have been shown to reg-
ulate the transcriptional activity of Ets1 by modulating
Ets1 DNA binding affinity (Fig. 4). AML-1, Pit-1 (pitui-
tary-specific transacting factor 1) and HIF-2α (hypoxia-
inducible factor 2α) bind to the exon VII domain and
block the inhibitory module of Ets1 [49,50,64,73]. In
turn, Ets1 may also increase the DNA binding activity of
its partner. E.g., Ets1 stimulates DNA binding activity of
AML-1 by associating with its NRDB domain (negative
regulatory domain for DNA binding) [50,89] (Fig. 4). In
the presence of a palindromic Ets binding site, the exon
VII domain also mediates homodimerization of Ets1 pro-
teins [61]. The dimerization blocks the autoinhibitory
mechanism allowing these proteins to mutually increase
their DNA binding activities and to bind cooperatively to
DNA. Pax5 (paired box containing gene 5), a transcription
factor that contacts the Ets domain of Ets1, uses a different
way to increase Ets1 affinity to DNA. It reorientates Tyr-
395 of the DNA-contacting helix 3 such that Ets1 can even
bind to an unfavorable GGAG containing element [70].
Often, synergism between Ets1 and another transcription
factor require certain stimuli to induce activation and/or
recruitment of the Ets1 interaction partner. Both phorbol
ester and ionomycin are needed for the cooperative effect
of Ets1 with GATA3 on the human interleukin-5 (IL-5)
promoter, for the synergistic action of Ets1 with AP1 (acti-
vator protein 1)and NFκB (nuclear factor of κB) on the
granulocyte-macrophage colony stimulating factor (GM-
CSF) promoter and for the ability of Ets1 and Stat5 to
cooperatively activate promoters through a GAS (inter-
feron  γ-activated sequence)/Ets combinatorial element
[56,63,84]. Whereas, TGFβ (transforming growth factor β)
is essential for the synergistic action of Ets1 and Smad3
(Sma/Mother against Decapentaplegic) on the PTHrP
(parathyroid-hormone-related protein) P3 promoter [77].
However, the importance of vitamin D for the functional
interaction of Ets1 with the vitamin D receptor (VDR)
seems to depend on the target gene. While vitamin D wasMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/29
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Proteins that physically interact with Ets1 Figure 3
Proteins that physically interact with Ets1. Proteins that cooperate with Ets1 to activate genes are shown in light yellow, 
proteins that either repress Ets1 activity or cooperate with Ets1 to repress gene activity are shown in pink. Proteins whose 
specific sites of interaction on the Ets1 protein are not yet defined (Sp1, HTLV-I Tax, mut p53) are indicated below. AML1 = 
acute-myeloid-leukemia-1, AP-1 = activator protein 1, ATF2 = activating transcription factor 2, CBP = CREB binding protein, 
ERK1/2 = extracellular-signal-regulated kinase 1/2, HIF-2α = hypoxia-inducible factor 2α, HTLV-I Tax = human T-cell lympho-
tropic virus-I transactivating protein of region X, MafB = musculoaponeurotic fibrosarcoma B, NFAT = nuclear factor of acti-
vated T-cells, Pax5 = paired box containing gene 5, Pit-1 = pituitary-specific trans-acting factor 1, Sp100 = speckled, 100 kD, 
Stat5 = signal transducer and activators of transcription 5, EAP = Ets1-associated protein, UBC9 = ubiquitin-conjugating 
enzyme 9, USF-1 = upstream stimulatory factor 1, VDR = vitamin D receptor
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required for the Ets1/VDR synergistic effect on the rat
cytochrome P450C24 gene promoter [90], it was dispen-
sable for the Ets1/VDR combined effect on rat prolactin
promoter [62]. The cooperative action of Ets1 with a
transcription factor is sometimes mediated by a co-factor.
This is the case for the Ets1/wildtype p53 synergism,
where CBP is required for the interaction between these
two proteins [76]. The combinatorial effect of Ets1 with
another transcription factor can also lead to gene repres-
sion. This has been shown for the interaction of Ets1 with
Daxx/EAPI (Ets1 associated protein I) which induces the
suppression of the bcl2 and mmp1 genes [87].
Some nuclear proteins, EAPI/II, MafB and ZEB, are able to
inhibit the transcriptional activity of Ets1 [55,67,88]. ZEB-
induced Ets1 repression can be relieved by c-Myb, a pro-
tein that can synergize with Ets1 [67].
Kinases
Several kinases have been demonstrated to phosphorylate
Ets1 and modulate its activity. Among them is calmodu-
lin-dependent kinase II (CaMKII) which can mimick
calcium in its ability to induce phosphorylation of the
exon VII domain [32,47]. This blocks Ets1 DNA binding
activity and, hence, inhibits Ets1 transcriptional activity.
Ternary complexes of Ets1 with AML1, Pit-1 or Pax5 and DNA Figure 4
Ternary complexes of Ets1 with AML1, Pit-1 or Pax5 and DNA. TAD = transactivation domain, NRDB = negative reg-
ulatory domain for DNA binding (autoinhibitory domain of AML1), runt = DNA binding domain of AML1, POU-HD = POU 
homeo domain (C-terminal DNA binding domain of Pit-1), POU-S = POU-specific (N-terminal DNA binding domain of Pit-1), 
CTD = C-terminal DNA binding domain of Pax5, NTD = N-terminal DNA binding domain.
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Recent data suggest that this inactivation may even con-
vert Ets1 from an activator to a repressor protein. This has
been shown for the GM-CSF (granulocyte/macrophage-
colony stimulating factor) promoter, whose activity was
found to be repressed when CaMKII-phosphorylated Ets1
was present [47]. It is thought that CaMKII-inactivated
Ets1 may act as a dominant negative protein by interfering
with the activity of related, CaMKII-resistant Ets proteins,
such as ∆VII-Ets1. Besides CaMKII, also myosin light-
chain kinase (MLCK) and a constitutively active form of
protein kinase Cα (PKCα) are able to phosphorylate the
exon VII domain [74,91]. Like CaMKII, MLCK was shown
to inactivate Ets1 [91], whereas PKCα increased the
transcriptional activity of Ets1 [74]. Whether exon VII
phosphorylation and Ets1 activation by PKCα are inde-
pendent events or whether the PKCα-mediated exon VII
phosphorylation is different to that induced by CaMKII
and MLCK remains to be seen. In support of the latter,
PKCα-dependent exon VII phosphorylation was found to
be independent of calcium [74], whereas, like CaMKII,
MLCK mediates calcium-dependent exon VII phosphor-
ylation [91]. Phosphorylation of the exon VII domain was
also observed, when leukaemic cells go into mitosis [92].
The other known phosphorylation site on the Ets1 protein
is threonine-38. Activation of the GTPase Ras leads to
phosphorylation of threonine-38 and increased Ets1
activity [28,29]. The Ras effect is mediated by the mitogen
activated kinases ERK1 and ERK2, the two effector kinases
of the Ras/Raf/MEK(MAPK/ERK kinase 1)/ERK 1/2 (extra-
cellular-signal-regulated kinase) pathway [28,29,59,93].
Phosphorylation of threonine-38 requires docking of ERK
onto the PNT domain [60]. Typical Ras responsive genes
harbor combinatorial Ets1/AP1 recognition motives
through which Ets1 and AP1 synergistically activate tran-
scription when stimulated by Ras [94]. Cooperative effects
with Ras have also been reported for other Ets proteins,
namely Ets2 and Drosophila  Pointed. In both cases, a
sequence similar to (114)LXLXXXF(120), which is crucial
for ERK binding, is present within the PNT domain. Also
a kinase-sensitive threonine is located exactly 16 amino
acids upstream from the PNT domain. This suggests that
the mechanism by which Ras induces phosphorylation of
Ets1-related proteins is conserved.
Acetyl transferases
Ets1 interacts with the acetyl transferases CBP/p300 and
ATF-2 (activating transcription factor 2) [42,48,58]. ATF-
2, originally defined as a CRE (cAMP responsive element)-
binding transcription factor, has recently also found to
display acetyl transferase activity [95]. Interestingly, CBP
and ATF-2 are the only Ets1-interacting proteins that so far
have been demonstrated to associate with the transactiva-
tion domain of the Ets1 protein [42,48]. This may suggest
that they serve a common function, such as acetylating
histones in response to Ets1 recruitment to an Ets1-regu-
lated promoter. ATF-2 has been demonstrated to support
Ets1-dependent activation of the T-cell receptor α (TCRα)
gene in cooperation with the transcription factors AML-1
and LEF-1 (lymphocyte enhancer-binding factor 1)/TCF
(T-cell factor) [48]. CPB and p300 are required for the syn-
ergistic action of Ets1 and wildtype p53 on pro-apoptotic
genes in embryonal stem cells [76] and increased induc-
tion of the MMP-3 (matrix metalloprotease-3) promoter
by Ets1 [58]. Recently, Ets1 has been reported to be itself
a target for acetyl transferases. When treated with TGFβ,
human dermal fibroblasts were found to acetylate Ets1
[96]. This was accompanied by inhibition of TGFβ-
dependent gene expression. Since Ets1 can also synergize
with TGFβ to activate genes [77], it is possible that acetyla-
tion triggers Ets1 to display an anti-TGFβ activity.
Ets1 expression
The Ets1 protein is produced by a variety of tissues. In
most cases, its truncated form, ∆VII-Ets1, is expressed
along with full-length Ets1. However, ∆VII-Ets1 is barely
detectable in astrocytes, astrocytoma and invasive mam-
mary carcinoma cells [91,97].
The lymphoid and haematopoietic tissue
In adults, expression of Ets1 was originally thought to be
restricted to lymphoid tissues [8]. Here, Ets1 is present in
T- and B-cells at all stages of their development [98]. Ets1
is also expressed in natural killer cells [99]. In chicken, it
seems that resting peripheral blood mononuclear cells
produce less Ets1 than cells of thymus, spleen and bursa
[100]. In the same species, Ets1 expression increased
when T-cells were activated and correlated well with the
presence of CD-28. In contrast, the Ets1 level was reported
to be downregulated in human T-cells upon activation
[101,102]. Ets1 is also expressed in erythroid cells, where
it is upregulated during differentiation [103].
The vascular system
Ets1 is also detected in other tissues. The two main blood
vessel forming cell types, endothelial cells (EC) and vascu-
lar smooth muscle cells (VSMC), transiently produce Ets1
upon activation by angiogenic factors, such as vascular
endothelial growth factor (VEGF), basic fibroblast growth
factor (bFGF), angiotensin II, endothelin-1, tumor necro-
sis factor α (TNFα) or hydrogen peroxide [104–108]. Acti-
vation of ECs and VSMCs results in proliferation,
migration and invasion of these cells [109]. Inhibition of
Ets1 expression by trans-dominant negative Ets1 mutant
proteins or by anti-sense oligonucleotides directed against
Ets1 abrogated the ability of ECs to migrate, to adopt an
invasive behavior or to form tubes in response to ang-
iogenic growth factors [107,110–112]. Conversely, consti-
tutive Ets1 expression mimicked angiogenic stimulation
and induced an invasive phenotype [113]. In addition,Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/29
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inhibition of Ets1 activity was shown to suppress hepato-
cyte growth factor (HGF) and FGF-2 induced angiogenesis
in animals [114,115]. During the menstrual cycle, EC-
dependent Ets1 expression increases in the proliferative
phase and drops in the secretory phase, following changes
in the VEGF level [116]. During pregnancy, Ets1 is found
Table 2: Ets1 expression in tumors
tumor of cancer type tumoral expression stromal(S)/vascular (V) 
expression
comments reference
brain astrocytoma 0% (grade II), 25% 
(III), 65% (IV)
high expression in glioma 
microvasculature
higher expression in 
recurrent vs. primary 
tumors;
[23,91,133]
meningioma benign (38%), 
invasive (86%)
invasive tumor: correlation 
with uPA expression
[134]
breast invasive carcinoma, 
DCIS, LCIS invasive 
cell lines
62% correlates with VEGF, 
MMP1 and MMP9 
expression
prognostic marker for poor 
prognosis
[74,97,128,135,
136]
cartilage/bone (jaw) chondro-sarcoma 60% [137]
osteosarcoma 0%
cervix cervical carcinoma correlates with TMD correlates with poor 
prognosis
[127]
colon/rectum adenomas 0–44% [126,138,139]
colon cancer 48–84% 65% (V) correlates with 
TMD, 28% (S) correlated 
with lung metastasis
vascular Ets1: linked with 
LNM and poor prognosis
endometrium endometrial 
carcinoma
correlates with TMD associates with histological 
grade, detected in cytoplasm
[24,125]
esophagus squamous carcinoma correlates with VEGF heterogenous expression, 
higher at invasive sites
[140,141]
liver/biliary tract hepatocellular 
carcinoma
50–100% higher in poorly 
differentiated tumors
[142]
bile duct carcinoma 61% higher in well-differentiated 
tumors
[143]
cholangio-cellular 
carcinomas
22%
lung pulmonary adeno-
carcinoma
linked to LNM [130,144]
lymphoid tissue T-leukemic cells (T-
ALL, ATL)
[132]
mouth squamous cell 
carcinoma
58% correlates with tumor stage 
and LNM
[131]
ovary benign cystadenoma 0% [25,129,145]
carcinoma 42%, higher when 
stroma is invaded
33% (S), correlates with 
MMP1 and MMP9 
expression
associated with poor 
prognosis
pankreas adeno-carcinoma 81% lower in poorly 
differentiated carcinoma
[146]
stomach adenomas 0% [147,148]
adeno-carcinoma 64% correlates with TMD
mucosal carcinoma 12%
thymus thymoma higher in higher grade 
tumors
[149]
thyroid gland thyroid carcinoma 40% (adenomas), 
50–98% (carcinoma)
[150]
vascular system 
(skin)
haemangioma weak [151]
granuloma 
pyogenicum
weak
angiosarcoma strong expression correlates with MMP1 
expression
TMD = tumor microvessel density, LNM = lymph node metastasis, DCIS = ductal carcinoma in situ, LCIS = lobular carcinoma in situMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/29
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in endothelial cells of the villous trophoblast, but not in
ECs of maternal endothelial cells [117]. In the developing
hypothalamo-hypophyseal system of the rat, Ets1 is
detected during angiogenesis [118]. Under pathological
conditions, Ets1 is produced by ECs that form new blood
vessels in the synovial membrane of the joint in patients
with active rheumatoid arthritis [119,120], by ECs of the
ulcerous gastric mocusa during the early phase of the heal-
ing process [121], in ECs within arteriovenous malforma-
tions [122] and, in rats, by ECs in the kidney during
glomerulonephritis [123]. Tumor-induced neo-angiogen-
esis also involves Ets1. Ets1 expression is found in the vas-
cular stroma of cancerous lesions [124] and often
correlates with tumor microvessel density [23,125–127].
In colon cancer, vascular Ets1 expression was associated
with poor prognosis and higher incidence of lymph node
metastasis [126].
Tumors
Ets1 is produced by a variety of solid tumors, including
epithelial tumors, sarcomas and astrocytomas (Tab. 2).
Dependent on the tumor type, Ets1 expression is either
increased or exclusively found in invasive higher grade
tumors. High Ets1 levels in breast, ovary and cervix carci-
noma correlates with poorer prognosis [25,127–129].
Ets1 was found to be an independent prognostic marker
of breast cancer that was not linked to other tumor mark-
ers, such as nodal status, tumor size, histological grade or
estrogen receptor status [128]. In lung, colorectal and
squamous cell carcinoma, Ets1 expression was associated
with a higher incidence of lymph node metastasis
[126,130,131]. In endometrial and ovarian cancer, the
presence of Ets1 correlated with a higher histological
grade [24,25]. In addition to advanced solid tumors, high
Ets1 expression has also found in leukemic T-cells [132].
Other tissues
Ets1 is also expressed in astrocytes, in certain cells of the
ovary, in hepatic stellate cells as well as in glandular epi-
thelial cells and stromal cells of the endometrium during
the menstrual cycle [91,152–154]. When murine breast
epithelial cells were stimulated to form tubules, Ets1
mRNA was detected at their growing tips [155]. Fibrob-
lasts in tumor-associated stroma, but not in normal tissue
has also been found to be Ets1 positive [124]. High non-
vascular stromal Ets1 level in colon cancers was found to
be associated with a higher risk for developing metastastic
lesions in the lung [51]. In rats, progression of glomeru-
lonephritis was accompanied with Ets1 expression in
glomerular epithelial cells and interstitial cells [123].
Ets1 is also expressed in a variety of tissues throughout the
embryonal development [156]. During the first trimester
of pregnancy, Ets1 was found in extravillous trophoblastic
cells invading the uterine vessels [117]. At embryonic day
15 of murine embryo development, Ets1 could be
detected in all organs [157], whereas, later, Ets1 was pre-
dominantly present in lymphoid tissues, brain and other
organs during branching morphogenesis. In the develop-
ing nervous system, Ets1 could be detected in the neural
pituitary and adenohypophysis at early stages and in the
hypothalamic magnocellular nuclei at later stages [118] as
well as in the hindbrain regions, neural tube, neural crest
and in the first and second branchial arches [158]. Ets1
was also found in developing vascular structures, such as
heart, arteries, capillaries and meninges. In the developing
bone, Ets1 is found in mesenchymal cells, whereas Ets1 is
not detected in the cartilage [159].
Regulation of Ets1 expression
Ets1 expression can be modulated by a variety of factors
(Fig. 5). The human Ets1 promoter is a TATA-less pro-
moter containing both positive and negative regulatory
elements [160]. Among the positive elements are binding
sites for Ets1, AP1, AP2 and Sp1 in the proximal part of the
promoter. More upstream, recognition sequence for Oct
and another Ets site and the two negative regulatory ele-
ments are found. The Ets1/AP1 combinatorial element
allows positive autoregulation of the Ets1 gene by a coop-
erative Ets1/AP1 interaction [161,162]. Recently, recogni-
tion elements for retinoic acid receptor and for hypoxia-
inducible factor HIF-1 have also been identified, through
which retinoic acid or hypoxia, respectively, activates Ets1
transcription [163–165]. Ets1 synthesis is also induced by
HGF (hepatocyte growth factor), PDGF (platelet-derived
growth factor) or TNFα (tumor necrosis factor α) via acti-
vation of the Ras/Raf/MEK1/ERK1/2 pathway
[59,108,166]. In breast carcinoma, melanoma and oste-
osarcoma cells, Ets1 expression is controlled by protein
kinase C (PKC) ([77] and J. Dittmer, unpublished results).
In activated endothelial cells, the MAP kinase p38 is
involved in Ets1 regulation [104]. In invasive breast can-
cer cells, Ets1 expression can be induced by TGFβ [167].
Some factors have been shown to repress Ets1 expression.
Wildtype p53, but not mutant p53, was found to repress
the Ets1 promoter [15] and, in endothelial cells, retinoic
acid negatively modulates Ets1 expression [168]. Different
regions of the Ets1 promoter drive Ets1 expression during
murine embryonal development [169]. A 2.4 kbp 5'-
flanking sequence is sufficient to allow Ets1 transcription
in the neural tube at gestational day 8.5, whereas also the
first exon and 9 kpb of the first intron are required for Ets1
expression in the developing vessels, meninges and chor-
iod plexus. This suggest a rather complex regulation of
Ets1 gene activity.
Ets1 function
Numerous genes have been shown to respond to the tran-
scription factor Ets1 [22]. However, whether a particular
gene is indeed regulated by Ets1 or, alternatively, by aMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/29
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related Ets factor can often not be answered with certainty.
To address this problem, Ets1-specific anti-sense technol-
ogy and trans-dominant negative protein treatments are
frequently applied. However, neither method is as specific
as desirable. Trans-dominant Ets1 proteins may poten-
tially also interfere with the function of closely related Ets
proteins, such as Ets2. Likewise, non-specific interactions
of anti-sense oligonucleotides may also affect the expres-
sion of unrelated genes [170]. Nevertheless, based on data
obtained by such approaches and by the knock-out tech-
nology in mouse a number of major functions has been
ascribed to Ets1 (Fig. 6). Some of those are of more gen-
eral importance, others are cell-type specific.
Haematopoietic development
Ets1 plays an important role in the development of lym-
phoid tissues [156]. By applying the knock-out technol-
ogy in mouse, a link between the presence of Ets1 and T-
lymphocyte activation was established, showing that Ets1-
deficient T-cells are defective in responding to activation
signals and are more prone to undergo apoptosis
[171,172]. Ets1 is also required for the development of
natural killer cells [99]. In cooperation with AML-1, which
is primarily expressed in T-cells [173], Ets1 activates a vari-
ety of T-cell specific genes, such as TCRα and β [48,50].
The transcription factors LEF-1/TCF and ATF-2 support
the AML-1/Ets1 cooperative effect on TCRα expression
[48]. The Ets1-Stat5 synergism plays a role in the activa-
tion of genes in response to T-cell activation [84]. In the
Th2 subtype of T-helper cells, Th2-specific transcription
factor GATA3 is able to functionally interact with Ets1 to
transactivate the interleukin-5 promoter [63]. A function
of Ets1 is also proposed for B-cell development. The mb-1
(immunoglobulin alpha chain) gene which is involved in
B-cell maturation has been demonstrated to be activated
by a concerted action of Ets1 with the B-cell specific acti-
vator protein Pax5 [71,72]. A role for Ets1 in regulating
the immunoglobulin heavy chain gene enhancer in B-cells
Factors that modulate Ets1 expression Figure 5
Factors that modulate Ets1 expression. Transcription factors that directly bind to the Ets1 promoter are shown in light 
yellow, kinases are in orange, growth factors and other factors are in green. AP-1 = activator protein 1, ERK1/2 = extracellu-
lar-signal-regulated kinase 1/2, HGF = hepatocyte growth factor, HIF-1 = hypoxia-inducible factor 1, PDGF = platelet derived 
growth factor, PKC = protein kinase C, RA = retinoic acid, RAR = retinoic acid receptor, TNFα = tumor necrosis factor α, wt 
p53 = wildtype p53.
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by cooperating with TFE3 and the distantly related Ets fac-
tor PU.1 has also been suggested [46]. In addition, it
seems that Ets1 can inhibit the differentiation of B-cells to
plasma cells [171,172]. In erythroid differentiation, Ets1
expression is linked to hemoglobinization [103]. Ets1 is
suggested to regulate genes that are involved in heme syn-
thesis [174]. Accordingly, Ets1-interacting protein MafB
downregulates transferrin receptor gene and porpho-
bilinogen deaminase expression by repressing Ets1 activ-
ity [88]. The haematopoietic transcription factor c-Myb
cooperates with Ets1 to transactivate the promoters of
important haematopoietic cell markers, such as mim-1
and α4 integrin [67,68]. Also janus kinase 3 (Jak3), a non-
receptor tyrosine kinase that is predominantly expressed
in haematopoietic cells and that is important for cytokine-
mediated activation, is under the control of Ets transcrip-
tion factors [175]. Chromatin immunoprecipitation
assays revealed that Ets1/2 binds to the Jak3 promoter.
Invasiveness and tumor progression
The Ets1 protein has oncogenic potential. It is able to
transform murine NIH3T3 cells [162] and it allows rat
embryo fibroblasts to grow in serum-free medium [176].
There is also a growing body of evidence that Ets1 plays a
key role in the acquisition of an invasive behavior. How
could Ets1 regulate invasiveness? Among the genes that
respond to Ets1 are those that code for certain proteases,
such as matrix metalloproteases MMP-1, MMP-3, MMP-9,
Main proposed functions of Ets1 in mammals Figure 6
Main proposed functions of Ets1 in mammals. Only some of the potential Ets1 target genes are shown, ES = embryonic 
stem cells, EC = endothelial cells, VSMC = vascular smooth muscle cells, TCR = T-cell receptor, Ig = immunoglobulin, Tfr = 
transferrin receptor, VEGF = vascular endothelial growth factor, VEGFR = VEGF receptor
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and urokinase type plasminogen activator (uPA) [22].
These proteases are known to be involved in ECM (extra-
cellular matrix)-degradion, a key event in invasion. In
angiosarcoma of the skin, Ets1 is co-expressed with MMP-
1 [151]. Ovarial carcinoma cells and stromal fibroblasts in
breast and ovarian cancer produce MMP-1 and MMP-9
along with Ets1 [135,145]. In lung and brain tumors, Ets1
expression correlates with that of uPA [134,144,177].
Similarily, some maternal cell populations during mouse
implantation and placentation were found to co-express
uPA and Ets1 [178]. However, not always does Ets1 and
uPA production overlap, as shown for trophoblasts that
heavily synthesize uPA although they lack Ets1 [178]. By
modulating Ets1 activity further evidence for a link
between Ets1 and certain proteases could be accumulated.
Inhibition of Ets1 expression in activated endothelial cells
by anti-sense DNA reduced the synthesis of MMP-1 and
uPA [110–112,115]. Introduction of a trans-dominant
negative form of Ets1 into Ets1-expressing epithelial cell
lines blunted the activity of uPA [155]. In invasive MDA-
MB-231 breast cancer cells, RNA interference-mediated
downregulation of Ets1 down-modulated the expression
of MMP-1 and MMP-9, but not that of MMP-3 and uPA (J.
Dittmer, unpublished results). When overexpressed in
endothelial cells or hepatoma cells, Ets1 induced the pro-
duction of MMP-1, MMP-3 plus MMP-9 or MMP-1, MMP-
9 plus uPA, respectively [113,179,180]. It seems that the
cellular context dictates whether a certain protease is reg-
ulated by Ets1 or not.
The integrin αv subunit also promotes migration and inva-
sion of cells and is involved in MMP activation [181]. In
glioma cells, expression of the integrin αv gene, which con-
tains Ets binding sites [182], was found to be reduced in
the presence of a transdominant-negative form of Ets1
[183]. There is also growing evidence demonstrating that
Ets1 may be involved in the regulation of c-Met, the recep-
tor of hepatocyte growth factor/scatter factor (HGF/SF). c-
Met induces migration ("scattering"), proliferation and
epithelial tube formation [184]. In esophageal cancer,
Met expression was found to correlate with that of Ets1
[141]. In murine liver progenitor cells and hepatoma cell
lines, Ets1 was shown to induce c-Met expression and to
render hepatoma cells more susceptible to HGF/SF
[180,185]. Also Epstein-Barr virus specific LMP-1 (latent
membrane protein-1)-mediated induction of Ets1 expres-
sion in MDCK epithelial cells resulted in an increased pro-
duction of c-Met, which could be prevented by addition of
a trans-dominant negative form of Ets1 [186]. In endothe-
lial cells, c-Met and HGF/SF expression could be reduced
by anti-sense DNA directed against Ets1 [115] and high
glucose treatment decreased both HGF/SF and Ets1 [187].
Conversely, c-Met also activates Ets1, as HGF/SF is able to
stimulate Ets1 activity in MDCK cells through the Ras/Raf/
MEK1/ERK1/2 pathway [59] and to induce Ets1 expres-
sion in endothelial cells [115]. Ets1 may even be an effec-
tor of c-Met. Not only was Ets1 found to mediate the effect
of HGF/SF on MMP1 in human hepatic stellate cells
[188], but it was also demonstrated to be capable of mim-
icking c-Met in its ability to induce "scattering" of liver
progenitor cells [185].
A number of other Ets1-responsive genes are known to be
involved in tumor progression. Among them is PTHrP
[80,189], expressed by numerous tumors and inducer of
hypercalcaemia of malignancy [190]. It is not only a
potent angiogenic factor [191], but also promotes expan-
sion of metastatic breast cancer cells in the bone by induc-
ing bone degradation [192]. This leads to activation of
TGFβ which further stimulates PTHrP gene expression.
The TGFβ effect on PTHrP involves a synergistic action
between Ets1 and Smad3 and is attentuated by inhibitors
that abrogate Ets1 expression [77].
Overexpression of the multidrug resistance (MDR) gene
increases aggressive behavior of MCF-7 cells [193].
Mutant, but not wildtype, p53 was found to cooperate
with Ets1 to increase the transcription from the MDR gene
[75]. The N-acetylglucosaminyltransferase V (GlcNAc-TV)
has also been reported to be a target of Ets1 [194]. Expres-
sion of GlcNAc-TV, a Golgi enzyme that catalyzes β 1,6-
GlcNAc-branching of N-glycans, is associated with meta-
static activities of tumor cells [195].
An additional new function of Ets1 emerged when Ets1
was found to interact with Sp100 [45], a component of
PML (promyelocytic leukemia protein) oncogenic
domains (PODs), nuclear bodies, which harbor also a
number of other proteins, such as p53, Rb and Ets1-inter-
acting Daxx/EAPI [196]. It could be shown that Ets1
decreased the number of PODs in HeLa cells [45]. Since
PML can act as a tumor suppressor [197], Ets1 may, by
interfering with PODs, negatively influence PML function
and promote tumorigenesis. Several important cellular
processes, such as apoptosis, cell proliferation and senes-
cence, are ascribed to PODs [196]. Ets1 may participate in
controlling some of these events. In support of this
notion, Ets1 has been shown to be involved in the regula-
tion of apoptosis (see below). Ets1 has also been found to
be overexpressed in senescent, but not in young normal
human fibroblasts [198]. The effect of Ets1 on PODs may
involve sumoylation. By sumoylation an approximately
100 kD protein, called SUMO (small ubiquitin-like mod-
ifier), is ligated to another protein [199]. This process
requires ubiquitin conjugating enzyme Ubc9 which has
been shown to interact with Ets1 and to enhance its tran-
scriptional activity [85]. Sumoylation of TEL, an Ets
repressor protein, leads to the formation of TEL nuclear
bodies [200]. This process requires Ubc9 to bind to the
POINTED domain of TEL. Sumoylation seems to beMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/29
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important for packaging proteins in nuclear bodies and
may effect the activity of transcription factors.
Angiogenesis
It has been well documented that Ets1 is required for
endothelial cells to adopt an angiogenic, blood vessel
forming phenotype [110–113,201]. Since acquisition of
invasive behavior is part of the endothelial activation pro-
gram, Ets1 may be responsible for stimulating the
necessary proteases [202]. However, it seems that Ets1 ful-
fills other functions in angiogenesis as well [203]. Anti-
sense DNA directed against Ets1 downregulated VEGF
expression in endothelial cells [115] suggesting that the
VEGF production by endothelial cells is regulated by Ets1.
Furthermore, VEGF was found to be co-expressed together
with Ets1 in the vascular stroma of endometrial and color-
ectal carcinoma [125,126]. Ets1 was also found to activate
the promoter of the endothelial VEGF receptor 1 gene, flt-
1, [204]. Accordingly, production of Ets1 and of the VEGF
receptor 1 (VEGFR-1) was co-induced in endothelial cells
that was co-cultured with estrogen-treated breast cancer
cells [201]. Also, endothelial expression of VEGFR-1 cor-
related with that of Ets1 in astrocytic cancers [23]. In addi-
tion, by cooperating with the hypoxia-inducible factor
HIF-2α, Ets1 is able to induce transcription from the
VEGFR-2 (VEGF receptor 2) gene (flk-1) promoter [64].
However, in contrast to VEGFR-1 production, VEGFR-2
expression was not associated with Ets1 expression in
astrocytic cancers [23]. The RNA level of neuropilin, an
enhancer of the VEGF-A effect, was also found to be linked
to Ets1 activity. It was increased in the presence of Ets1
and decreased when Ets1 activity was suppressed [205].
Thus, Ets1 seems be involved in the regulation of activities
of VEGF and its receptors. As was proposed for the c-Met/
HGF/SF-Ets1 cooperativity, a positive feedback loop may
exist for the Ets1/VEGF interaction. By inducing Ets1
expression, VEGF may trigger its own production leading
to further Ets1 synthesis, finally resulting in endothelial
cell activation. However, the function of Ets1 in endothe-
lial cells may be more complex. Overexpression of Ets1
can also lead to reduced growth activity of endothelial
cells at higher cellular density [206]. This is accompanied
by an increased expression of VE-cadherin, which plays an
important role in vascular morphogenesis and growth
control.
Apoptosis
There are conflicting data on the role of Ets1 in apoptosis.
On the one hand, Ets1-deficiency increases T-cells apopto-
sis [171,172] and overexpression of Ets1 protects VSMCs
from undergoing apoptosis by activating p21WAF1/Cip1
[207]. On the other hand, deletion of the Ets1 gene cells
render embryonic stem cells resistant to UV-induced
apoptosis [76]. In this case, Ets1 acts synergistically with
wildtype p53 to activate p53-responsive pro-apoptotic
genes, such as bax. Similarly, Ets1 induces apoptosis in
endothelial cells by stimulating the expression of pro-
apoptotic genes, such as bid [202,208]. In colon cancer
cells, Ets1 cooperates with Daxx/EAPI to suppress expres-
sion of the anti-apoptotic Bcl2 [87]. This effect may be
linked to the ability of Ets1 to regulate the activity of
PODs, since PODs contain Daxx/EAPI (see above). Also
in colon cancer cells, the natural Ets1 variant ∆VII-Ets1
was found to induce the expression of caspase 1 and to
render these cells more susceptible to Fas-mediated apop-
tosis [209]. When overexpressed in invasive breast cancer
cells, ∆VII-Ets1 reduced the survival of these cells [97].
Invasive cancer cells that depend on Ets1 may, therefore,
be forced to protect themselves against the pro-apoptotic
effect of Ets1, in particular of ∆VII-Ets1. One way to do
this is by adopting a mechanism that selectively suppress
expression of ∆VII-Ets1 [97]. T-cells in the contrary, where
Ets1 acts anti-apoptotically, may tolerate high protein lev-
els of ∆VII-Ets1.
Other functions
The presence of Ets1 in a variety of murine embryonic tis-
sues, particular in the developing vascular system, in ang-
iogenically active tissues and in those organs that undergo
morphogenesis, suggest a fundamental role of Ets1 in
embryonic development. Yet, Ets1 k.o. mice develop
normally and are viable, although they show an increased
perinatal mortality [171]. On the other hand, when Ets1
was downregulated together with Ets2, chicken embryos
displayed defects in the epicardium, the coronary circula-
tion and in the myocardium [210] that resembled those
found in mice deficient in VCAM-1 (vascular cell adhe-
sion molecule 1) and α4 integrin [211,212], two Ets-
responsive genes [67,213]. Since no obvious effect on the
vascular system was reported when the Ets2 gene alone
was disrupted in mouse [214] it is likely that a double-
knock down of Ets1 plus Ets2 is required to induce defects
in the developing vascular system. Since Ets1 and Ets2
expression overlap in the developing embryo at some
areas, such as in the developing heart [156], Ets2 may par-
tially substitute for Ets1 in embryonic development. Sev-
eral genes involved in embryonic development have been
found to be Ets1-responsive. Among these are the gene
that codes for transcription factors AP-2α (activating pro-
tein 2α) which plays a pivotal role in differentiation of the
Ets1-expressing trophoblast [215].
The interaction of Ets1 with transcription factors, such as
AML-1, Pit-1 or Pax5 whose expression is limited to cer-
tain tissues, predicts that Ets1 serves functions in specific
tissues. As discussed above, AML-1/Ets1 and Pax-5/Ets1
cooperations may play important roles in T- and B-cell
differentiation, respectively. Pit-1 is specifically produced
by the anterior pituitary gland, where it is required for the
expression of various genes and for the development ofMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/29
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this gland [216,217]. Pit-1 cooperates with pituitary Ets1
to stimulate prolactin synthesis [218,219] suggesting that
Ets1 plays also a role in pituitary hormone secretion.
Interaction of Ets1 with USF (upstream stimulatory fac-
tor) [86] seems to mediate Ets1-dependent transactivation
of the DOR (δ-opioid receptor) gene through an EBS (Ets
binding site)/E-box combinatorial element in neuronal
cells [220].
Ets1 is also involved in viral transformation. Ets1 is
important for mediating transcriptional activation of spe-
cific genes by the transforming viral protein Tax, a transac-
tivator that is encoded by the region X of the human T-cell
lymphotropic virus I (HTLV-I). Being unable to bind to
DNA by itself, Tax interacts with transcription factors, to
get in close contact with the transcriptional machinery
[221]. Tax can bind directly to Ets1 and can form a ternary
complex with Ets1 and Sp1 [65]. Tax/Ets1 synergism is
involved in Tax-mediated activation of the PTHrP and
interleukin-5 promoter as well as of the HTLV-I LTR (long
terminal repeat) [63,189,222]. Ets1 was also shown to be
required for efficient transcription from the LTR of the
human immunodeficiency virus-1 (HIV-1) [69,86].
Accordingly, transdominant-negative Ets1 mutant protein
was found to suppress HIV replication in T-cells [223].
Conclusions
The currently available data demonstrate distinct roles for
Ets1 in haematopoietic cell differentiation. Ets1 seems
also to participate in the regulation of invasive behavior of
many normal and tumor cells alike. Adoption of invasive
behavior is an important step for endothelial cells to con-
vert to an angiogenic phenotype. Accordingly, Ets1 is
abundant in regenerating adult tissues or in areas of the
developing embryo that require new blood vessel to be
formed. Likewise, Ets1 is overexpressed in tissues under
pathological conditions that involve angiogenic activities.
The link between Ets1 and invasiveness is not limited to
endothelial cells, also vascular smooth muscle, epithelial
and fibroblastic cells seem to need Ets1 to become inva-
sive. For epithelial cancer, Ets1 may fulfill a dual function;
it may provide the cancer cells with nutrients and oxygen
by inducing tumor vascularization and it may promote
tumor invasion by activating ECM-degrading proteases in
the cancer and/or in stromal cells. Consequently, high lev-
els of Ets1 in tumors often correlates with poorer progno-
sis. Therefore, it would be desirable to develop therapies
that target the Ets1 gene. It seems that PKC is a major reg-
ulator of Ets1 expression in cancer cells. Thus, PKC inhib-
itors, which already entered clinical trials [224], may be a
useful tool to control Ets1 activity in cancer.
As mentioned above, the current understanding of the
Ets1 function is based on data partially obtained by meth-
ods which may not clearly allow distinction between the
involvement of Ets1 or that of another Ets protein. In
future, more reliable results may be obtained by using the
recently developed method of post-transcriptional
silencing by RNA interference [225]. In addition, new
DNA binding assays, such as chromatin immunoprecipi-
tation assays, may help to demonstrate direct binding of
Ets1 to the gene of interest in vivo.
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